Newer therapeutic approaches for systemic lupus erythematosus: Immunosuppressive agents

被引：14

作者：

Dooley, MA ^{[1
]}

Ginzler, EM ^{[1
]}

机构：

[1] SUNY Hlth Sci Ctr, Dept Med, Downstate Internal Med Associates, Brooklyn, NY 11203 USA

来源：

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA | 2006年 / 32卷 / 01期

关键词：

D O I：

10.1016/j.rdc.2005.11.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There has been unprecedented growth in new therapeutic approaches for the treatment of systemic lupus erythematosus (SLE). These approaches include re-evaluation of die doses and duration of therapy with traditional agents, including intravenous cyclophosphamide and azathioprine. Drugs that were developed for other uses are being applied to specific SLE manifestations, and have spurred larger scale trials for overall disease activity In addition, several new agents show promise in clinical trials; many have safer toxicity profiles than do traditional therapies. Some of these agents have multiple immunomodulatory effects, whereas others interfere with a specific immunologic process in one of the pathogenetic pathways of SLE activity.

引用

页码：91 / +

页数：13

共 80 条

[51] B cells as therapeutic targets for rheumatic diseases [J].

Looney, RJ ;

Anolik, J ;

Sanz, I .

CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (03) :180-185

[52]

MARRA CA, 2002, ARTHRITIS RHEUM, V4, P1003

[53] Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study [J].

Mok, CC ;

Tong, KH ;

To, CH ;

Siu, YP ;

Au, TC .

KIDNEY INTERNATIONAL, 2005, 68 (02) :813-817

[54] Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis [J].

Mok, CC ;

Ying, KY ;

Tang, S ;

Leung, CY ;

Lee, KW ;

Ng, WL ;

Wong, RWS ;

Lau, CS .

ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2559-2568

[55] Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine [J].

Mok, CC ;

Ho, CTK ;

Chan, KW ;

Lau, CS ;

Wong, RWS .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1003-1013

[56] ''Nephritic flares'' are predictors of bad long-term renal outcome in lupus nephritis [J].

Moroni, G ;

Quaglini, S ;

Maccario, M ;

Banfi, G ;

Ponticelli, C .

KIDNEY INTERNATIONAL, 1996, 50 (06) :2047-2053

[57] Long-term efficacy of azathioprine treatment for proliferative lupus nephritis [J].

Nossent, HC ;

Koldingsnes, W .

RHEUMATOLOGY, 2000, 39 (09) :969-974

[58] Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis [J].

Ong, LM ;

Hooi, LS ;

Lim, TO ;

Goh, BL ;

Ahmad, G ;

Ghazalli, R ;

Teo, SM ;

Wong, HS ;

Tan, SY ;

Shaariah, W ;

Tan, CC ;

Morad, Z .

NEPHROLOGY, 2005, 10 (05) :504-510

[59] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus [J].

Perrotta, S ;

Locatelli, F ;

La Manna, A ;

Cennamo, L ;

De Stefano, P ;

Nobili, B .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :465-467

[60]

Petera P, 2000, ARTHRITIS RHEUM, V43, pS241

← 1 2 3 4 5 6 7 8 →